Alphamab Oncology ( ($HK:9966) ) has issued an update. Alphamab Oncology announced that its drug JSKN003, co-developed with Shanghai JMT-Bio ...

BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

The HER2-targeted ADC showed clear benefits over Roche's Kadcyla in the adjuvant setting, and promising activity versus standard neoadjuvant therapy.

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sacituzumab tirumotecan significantly ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...

Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.